AstraZeneca Pharma India shares may be in focus after the company announced a second brand partnership with Sun Pharma to expand nationwide access to Sodium Zirconium Cyclosilicate (SZC), a therapy for managing hyperkalemia. Under the agreement, both companies will promote, market and distribute SZC under separate brands to accelerate patient access to what AstraZeneca calls an innovative, effective treatment.